From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade

Area of Science:

• Oncology
• Cancer Metastasis
• Molecular Biology

Background:

• Bone metastasis is a frequent and severe complication of advanced prostate cancer (PCa).
• Tumor hypoxia is a key driver of PCa bone tropism, influencing epithelial-to-mesenchymal transition (EMT), cancer stemness, and extracellular matrix (ECM) remodeling.
• Hypoxia also promotes the formation of pre-metastatic niches and skeletal colonization via extracellular vesicles (EVs) and bone-homing molecules.

Purpose of the Study:

• To review the molecular mechanisms by which hypoxia orchestrates prostate cancer dissemination to bone.
• To explore therapeutic strategies targeting hypoxia-driven pathways for advanced and castration-resistant prostate cancer (CRPC).

Main Methods:

• Analysis of current evidence on hypoxia's role in PCa bone metastasis.
• Focus on molecular crosstalk between Hypoxia-Inducible Factor (HIF) signaling, Wnt activation, EV communication, and cellular plasticity.
• Examination of therapeutic strategies including HIF inhibitors, hypoxia-activated prodrugs, and Wnt antagonists.

Main Results:

• Hypoxia promotes PCa bone metastasis through EMT, stemness, ECM remodeling, and activation of Wnt/β-catenin and PI3K/Akt pathways.
• Hypoxia enhances EV secretion and upregulates bone-homing molecules (CXCR4, integrins, PIM kinases), facilitating niche formation.
• Therapeutic strategies targeting hypoxia pathways show promise in overcoming resistance in CRPC.

Conclusions:

• Understanding hypoxia's role in PCa bone metastasis is crucial for developing effective treatments.
• Targeting hypoxia-related pathways and molecular crosstalk presents promising avenues for improving outcomes in advanced PCa.
• Further research into these mechanisms can lead to novel therapeutic interventions for CRPC bone disease.